PMID- 27039822
OWN - NLM
STAT- MEDLINE
DCOM- 20170118
LR  - 20221207
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 17
IP  - 3
DP  - 2016
TI  - Safety and Management of Toxicity Related to Aflibercept in Combination with 
      Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic 
      Colorectal Cancer.
PG  - 973-8
AB  - BACKGROUND: Between October 2012 and February 2015, 25 patients with metastatic 
      colorectal cancer (mCRC) (mean age, 57.0 +/- 12.1 years) were granted access to 
      aflibercept via the Aflibercept Named Patient Program at four centers. MATERIALS 
      AND METHODS: Here we reported the initial experience of aflibercept / FOLFIRI in 
      combination. We evaluated treatment-related adverse events (AEs), 
      progression-free survival (PFS) and overall survival (OS). RESULTS: The majority 
      of the patients experienced gastrointestinal toxicity (grade 1-2), with diarrhea 
      (52%), mucositis (52%), and nausea/vomiting (20%) being largely observed. 
      Neutropenia (16%) and febrile neutropenia (8%) were common grade 3-4 
      hematological events. Aflibercept-related toxicity was managed as per practice 
      guidelines. No grade 5 event was reported. Median PFS was 6.12 months (95% CI, 
      4.80-7.20) and OS was 12 months (95% CI, 9.80-14.18). The partial response (PR), 
      stable disease (SD), and progressive disease (PD) rates were 25% (95% CI: 
      23.4-27.0), 37.5% (95% CI: 31.6-43.3), and 37.5% (95% CI: 22.5-52.5), 
      respectively. CONCLUSIONS: Aflibercept/FOLFIRI can be administered safely in a 
      second line setting to Malaysian patients with mCRC, as the AEs experienced were 
      generally reversible and manageable. The safety and efficacy outcomes were 
      consistent with those observed in Western populations.
FAU - Yusof, Mastura Md
AU  - Yusof MM
AD  - Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Malaysia E-mail : 
      drmasturamy@gmail.com.
FAU - Abdullah, Nik Ma
AU  - Abdullah NM
FAU - Sharial, Msn Mohd
AU  - Sharial MM
FAU - Zaatar, Adel
AU  - Zaatar A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - 7673326042 (Irinotecan)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - Asian People
MH  - Camptothecin/administration & dosage/adverse effects/analogs & derivatives
MH  - Colorectal Neoplasms/*drug therapy
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/*etiology
MH  - Female
MH  - Fluorouracil/administration & dosage/adverse effects
MH  - Humans
MH  - Irinotecan
MH  - Leucovorin/administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Receptors, Vascular Endothelial Growth Factor/administration & dosage
MH  - Recombinant Fusion Proteins/administration & dosage/adverse effects
MH  - Safety
EDAT- 2016/04/05 06:00
MHDA- 2017/01/19 06:00
CRDT- 2016/04/05 06:00
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2017/01/19 06:00 [medline]
AID - 10.7314/apjcp.2016.17.3.973 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2016;17(3):973-8. doi: 10.7314/apjcp.2016.17.3.973.